Prednisone
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1955
- First approval year
- 1955
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Prednisone
- Molecular weight
- 358.43
- Structure (SMILES)
- C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
- cortan
- Cortan
- cortancyl
- Cortancyl
- decortisyl
- Decortisyl
- delta dome
- Delta-dome
- deltasone
- Deltasone
- fernisone
- Fernisone
- liquid pred
- Liquid pred
- lodotra
- Lodotra
- meticorten
- Meticorten
- orasone
- Orasone
- paracort
- Paracort
- prednicen m
- Prednicen-m
- prednisone
And 9 more, listed on the interactive page.
- 0 mg prednisone
- 0 mg Prednisone
- 100mg prednisone suppository
- 3en3hg4wsw
- 5 days of systemic corticotherapy (prednisone)
- 5 mg prednisone
- 5 mg Prednisone
- 60 mg Prednisone
- Cortancyl
- Cortancyl Oral Tablet
- Corticosteroids (Prednisone)
- decortin
- Decortin
- dehydrocortisone
- Dehydrocortisone
- IR Prednisone
- Lodotra
- Lodotra®
- metacortandracin
- Metacortandracin
- nsc 10023
- NSC-10023
- oral prednisone
- Oral Prednisone
- Oral Prednisone 10mg
And 66 more, listed on the interactive page.
- CAS registry numbers
- 53-03-2
- ChEMBL ID
- CHEMBL635
- InChIKey
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N
- PubChem compound IDs
- 5865
- RxNorm IDs (RxCUI)
- 8640
- FDA ingredient codes (UNII)
- VB0R961HZT
- A07EA03
- H02AB07
Sources for recorded values
- Applicant
- SCHERING
- Approval date
- 21 Feb 1955
- Application number
- NDA009766
- Patents
- 2
- Designations
- 2
- Earliest recorded loss of exclusivity
- 7 Jan 2028
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Pharmacology name
- prednisone
- Type
- Synthetic organic
- Drug name stem
- pred-
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Mechanism
- Glucocorticoid receptor agonist
- Action type
- Agonist
- Target
- Glucocorticoid receptor
- Protein identifier
- P04150
- Action
- Full agonist
- Action type
- FULL_AGONIST
- Target
- Glucocorticoid receptor
- Gene symbol
- NR3C1
- Protein identifier
- P04150
- Median affinity
- 6.28
- Affinity units
- pKi
- Primary target
- Yes
Open Targets mechanisms
- Mechanism
- Glucocorticoid receptor agonist
- Action type
- Agonist
- Target
- Glucocorticoid receptor
DrugCentral mechanisms
- Action type
- Agonist
- Gene symbol
- NR3C1
- Protein identifier
- P04150
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Sarcoidosis, Pulmonary
- Highest recorded phase
- 3
- Condition identifier
- DOID:13406
- Subject identifier
- D017565
- Condition
- Leukemia, Biphenotypic, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000094
- Subject identifier
- D015456
- Condition
- Leukemia, Lymphocytic, Chronic, B-Cell
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000095
- Subject identifier
- D015451
- Condition
- Lymphoma, Follicular
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000096
- Subject identifier
- D008224
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Hodgkin Disease
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000183
- Subject identifier
- D006689
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000196
- Subject identifier
- D011471
- Condition
- Myelodysplastic Syndromes
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000198
- Subject identifier
- D009190
- Condition
- Neoplasms, Plasma Cell
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000200
- Subject identifier
- D054219
- Condition
- Leukemia, Biphenotypic, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000209
- Subject identifier
- D015456
- Condition
- Lymphoma, T-Cell, Peripheral
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000211
- Subject identifier
- D016411
- Condition
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000220
- Subject identifier
- D054198
- Condition
- Leukemia, Myeloid, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000222
- Subject identifier
- D015470
- Condition
- Immunoblastic Lymphadenopathy
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000255
- Subject identifier
- D007119
- Condition
- Dermatitis, Atopic
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000274
- Subject identifier
- D003876
- Condition
- Burkitt Lymphoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000309
- Subject identifier
- D002051
- Condition
- Cardiomyopathies
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000318
- Subject identifier
- D009202
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Heart Failure
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000373
- Subject identifier
- D006333
- Condition
- Crohn Disease
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000384
- Subject identifier
- D003424
- Condition
- Dermatomyositis
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000398
- Subject identifier
- D003882
- Condition
- Lymphoma, Large B-Cell, Diffuse
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000403
- Subject identifier
- D016403
- Condition
- Thrombocythemia, Essential
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000479
- Subject identifier
- D013920
- Condition
- Dermatomyositis
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000557
- Subject identifier
- D003882
- Condition
- Leukemia
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000565
- Subject identifier
- D007938
And 201 more, listed on the interactive page.
- Condition identifier
- DOID_13406
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000096
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000182
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000183
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000196
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000198
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000211
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000220
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000274
- Condition identifier
- EFO_0000318
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000341
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000373
- Condition identifier
- EFO_0000384
- Condition identifier
- EFO_0000398
- Condition identifier
- EFO_0000403
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000556
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000565
- Condition identifier
- EFO_0000574
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000673
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000676
- Condition identifier
- EFO_0000685
- Condition identifier
- EFO_0000729
- Condition identifier
- EFO_0000764
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000768
- Highest recorded phase
- 3
And 513 more, listed on the interactive page.
- Event
- abdominal discomfort
- Reports
- 2,787
- Reporting signal score
- 2,970.77
- Event
- alopecia
- Reports
- 2,978
- Reporting signal score
- 3,319.75
- Event
- anti-cyclic citrullinated peptide antibody positive
- Reports
- 1,133
- Reporting signal score
- 2,427.25
- Event
- arthropathy
- Reports
- 1,945
- Reporting signal score
- 2,687.45
- Event
- asthma
- Reports
- 1,850
- Reporting signal score
- 1,882.88
- Event
- cytomegalovirus infection
- Reports
- 2,232
- Reporting signal score
- 3,211.12
- Event
- discomfort
- Reports
- 1,315
- Reporting signal score
- 1,820.89
- Event
- drug intolerance
- Reports
- 2,395
- Reporting signal score
- 2,151.44
- Event
- duodenal ulcer perforation
- Reports
- 602
- Reporting signal score
- 1,581.07
- Event
- febrile neutropenia
- Reports
- 4,657
- Reporting signal score
- 4,056.77
- Event
- glossodynia
- Reports
- 2,021
- Reporting signal score
- 3,238.38
- Event
- hand deformity
- Reports
- 1,695
- Reporting signal score
- 3,087.57
- Event
- infusion related reaction
- Reports
- 1,701
- Reporting signal score
- 1,630.81
- Event
- joint swelling
- Reports
- 2,183
- Reporting signal score
- 1,981.54
- Event
- loss of personal independence in daily activities
- Reports
- 1,181
- Reporting signal score
- 1,889.41
- Event
- pain
- Reports
- 4,471
- Reporting signal score
- 1,825.61
- Event
- pemphigus
- Reports
- 2,586
- Reporting signal score
- 5,541.16
- Event
- pericarditis
- Reports
- 1,057
- Reporting signal score
- 1,987.29
- Event
- pneumocystis jirovecii pneumonia
- Reports
- 1,586
- Reporting signal score
- 2,653.37
- Event
- rheumatoid arthritis
- Reports
- 4,261
- Reporting signal score
- 2,537.14
- Event
- rheumatoid factor positive
- Reports
- 698
- Reporting signal score
- 1,814.09
- Event
- swelling
- Reports
- 2,307
- Reporting signal score
- 2,633.69
- Event
- synovitis
- Reports
- 1,612
- Reporting signal score
- 3,252.91
- Event
- systemic lupus erythematosus
- Reports
- 2,584
- Reporting signal score
- 3,459.76
- Event
- therapeutic product effect incomplete
- Reports
- 1,223
- Reporting signal score
- 1,473.8
And 2 more, listed on the interactive page.
- NCT00000146
- NCT01524250
- NCT00000178
- NCT00000421
- NCT00119678
- NCT00137969
- NCT00430677
- NCT00539838
- NCT00774852
- NCT01946880
- NCT02558517
- NCT05666336
- NCT00000524
- NCT00000596
- NCT00268515
- NCT05351554
- NCT00000819
- NCT00000921
- NCT01425099
- NCT00001563
- NCT00002524
- NCT00002571
- NCT00049036
- NCT00126243
- NCT01775475
And 1,075 more, listed on the interactive page.
- Dose
- 5-60mg
- How often
- Once daily
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 2
- Polar surface area
- 91.67
- Calculated partition coefficient (ALogP)
- 1.77
- Calculated partition coefficient (XLogP)
- 1.5
- Prodrug
- Yes
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 2
- Heavy atoms
- 26
- Molecular formula
- C21H26O5
- Monoisotopic mass
- 358.17802393
- Natural product
- Yes
- 0054-0017
- 0054-0018
- 0054-0019
- 0054-3721
- 0054-3722
- 0054-4728
- 0054-4741
- 0054-4742
- 0054-8724
- 0054-8739
- 0054-8740
- 0054-9817
- 0054-9818
- 0054-9828
- 0378-0640
- 0378-0641
- 0378-0642
- 0591-5052
- 0591-5442
- 0591-5443
- 0603-5335
- 0603-5336
- 0603-5337
- 0603-5338
- 0603-5339
And 285 more, listed on the interactive page.
- Recorded assays
- 6,456
- Active assays
- 73
- Confirmatory
- Other
- Screening
- Summary
- Anti-Inflammatory Agents
- Glucocorticoids
- Antineoplastic Agents, Hormonal
Distribution coefficient (LogD)
- Median
- 1.46
- Mean
- 1.46
- Minimum
- 1.46
- Maximum
- 1.46
- Unit
- unitless
- Assays
- 2
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- LogD
Oral bioavailability
- Median
- 80
- Mean
- 80
- Minimum
- 80
- Maximum
- 80
- Unit
- %
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (1,532)
- 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer
- A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma
- A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- A Clinical Study on the Combined Magnetic and Oxygen Treatment for Bell's Palsy
- A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
- A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
- A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE
- A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.
- A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer
- A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)
- A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)
- A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017)
- A First-in-Human Study to Learn How Well a Bi-Layer Calcium Carbonate Antacid Tablet Works Compared to a Standard, Non-Layered Calcium Carbonate Tablet in Healthy Male Participants
- A Multicenter Phase 2 Single-arm Proof-of-concept Trial to Assess the Efficacy and Safety of Ustekinumab in Association With Prednisone for the Treatment of Non-infectious Severe Uveitis (NISU)
- A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer
- A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma
- A Multicenter, Randomized, Controlled Trial of Prednisone Combined With Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis With Moderate to Severe Interface Hepatitis Characteristics
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Approved for (71)
- Adrenal gland disorder
- Allergic rhinitis
- Anemia
- Ankylosing spondylitis
- Aplastic anemia
- Arthritic joint disease
- Asthma
- Atopic conjunctivitis
- Atopic eczema
- Autoimmune thrombocytopenic purpura
- Brain neoplasm
- Bursitis
- Cancer
- Chorioretinitis
- Choroiditis
- Chronic beryllium disease
- Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency
- Contact dermatitis
- Crohn disease
- Dermatitis herpetiformis
In development for (147)
- Acquired polycythemia vera Phase 2
- Acute lymphoblastic leukemia Phase 3
- Acute myeloid leukemia Phase 3
- Adrenocortical insufficiency Phase 2
- Adult T-cell leukemia/lymphoma Phase 3
- AIDS Phase 2
- Alcoholic hepatitis Phase 2
- Allergic disease Phase 2
- Alzheimer disease Phase 3
- Amyotrophic lateral sclerosis Phase 2
- Anaplastic large cell lymphoma Phase 2
- Angioimmunoblastic T-cell lymphoma Phase 2
- Anti-neutrophil antibody associated vasculitis Phase 3
- Autoimmune disease Phase 2
- Autoimmune hemolytic anemia Phase 2
- Autoimmune hepatitis Phase 2
- B-cell acute lymphoblastic leukemia Phase 3
- B-cell chronic lymphocytic leukemia Phase 3
- B-cell non-Hodgkin lymphoma Phase 2
- Bell's palsy Phase 2
Other linked conditions (8)
- Cellulitis
- Chronic hepatitis B virus infection
- Glomerular disorder
- Hepatitis B virus infection
- Inflammatory bowel disease
- Restless legs syndrome
- Thyroid gland disorder
- Type IV hypersensitivity disease
Targets (1)
- NR3C1 Glucocorticoid receptor agonist